These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
99 related items for PubMed ID: 17610335
1. Perspectives on dynamic optimisation and control theory in treating hyperlipidaemia. Vernon JA. Pharmacoeconomics; 2007; 25(7):533-5. PubMed ID: 17610335 [No Abstract] [Full Text] [Related]
2. Epidemiology and economics of statin use. Feely J, Bennett K. Ir Med J; 2008 Jun; 101(6):188-91. PubMed ID: 18705057 [Abstract] [Full Text] [Related]
3. [Statines for all or individualized lipid lowering therapy?]. Parhofer K. MMW Fortschr Med; 2009 Apr 02; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849 [No Abstract] [Full Text] [Related]
4. Reducing expenditures for statin-type lipid-lowering agents. Am J Health Syst Pharm; 1998 May 15; 55(10):995-6, 999. PubMed ID: 9606450 [No Abstract] [Full Text] [Related]
5. [Analysis of pharmaco-economic assessments on anti-hypertension and anti-lipidemia medicines for Turkey]. Koçkaya G. Anadolu Kardiyol Derg; 2012 Mar 15; 12(2):188. PubMed ID: 22311872 [No Abstract] [Full Text] [Related]
6. Alternate-day statin therapy for the treatment of hyperlipidemia. Reindl EK, Wright BM, Wargo KA. Ann Pharmacother; 2010 Sep 15; 44(9):1459-70. PubMed ID: 20702760 [Abstract] [Full Text] [Related]
7. Statin use in children in the United States. Lasky T. Pediatrics; 2008 Dec 15; 122(6):1406-8; author reply 1408. PubMed ID: 19047265 [No Abstract] [Full Text] [Related]
8. Cost of cerivastatin in cost-effectiveness study. Chung KC, Pomerantz K, Harrison B. Am J Health Syst Pharm; 2000 Sep 15; 57(18):1712-3. PubMed ID: 11006802 [No Abstract] [Full Text] [Related]
9. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden. Martikainen JA, Soini E, Paulsson T. Curr Med Res Opin; 2010 Feb 15; 26(2):389-96. PubMed ID: 20001451 [Abstract] [Full Text] [Related]
10. Expanding statin use to help more at-risk patients is causing financial heartburn. Mitka M. JAMA; 2003 Nov 05; 290(17):2243-5. PubMed ID: 14600168 [No Abstract] [Full Text] [Related]
11. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS, Goa KL. Drugs; 2001 Nov 05; 61(12):1835-81. PubMed ID: 11693468 [Abstract] [Full Text] [Related]
12. Can taking statins to help control my cholesterol cause diabetes? Heart Advis; 2010 Jul 05; 13(7):8. PubMed ID: 23091867 [No Abstract] [Full Text] [Related]
13. The demand for statin: the effect of copay on utilization and compliance. Thiebaud P, Patel BV, Nichol MB. Health Econ; 2008 Jan 05; 17(1):83-97. PubMed ID: 17585395 [Abstract] [Full Text] [Related]
14. Hyperlipidaemia and cardiovascular disease: statin update. Roberts AW, Salim M. Curr Opin Lipidol; 2007 Jun 05; 18(3):381-3. PubMed ID: 17495613 [No Abstract] [Full Text] [Related]
15. What you should know about statin side effects. The benefits of these drugs far outweigh the risks. Heart Advis; 2010 Jun 05; 13(6):5. PubMed ID: 23166971 [No Abstract] [Full Text] [Related]
17. Is a pound of prevention better than an ounce of prevention? Mandell BF. Cleve Clin J Med; 2005 Sep 05; 72(9):729. PubMed ID: 16193820 [No Abstract] [Full Text] [Related]